MGI gene sequencing company

Location: Home /  News Center

MGI turns a new page in the human genome era with ultra-high throughout DNBSEQ-T7 sequencer*

Release date:2022-06-01Writer:MGIViews:418Share
Amidst the rapid evolution of DNA sequencing technologies in past years, the industry has been working tirelessly to make genomics more accessible. Since the Human Genome Project, which saw scientists from six countries coming together to map the first human genome at nearly $3 billion over 13 years, the cost of whole-genome sequencing has fallen to less than $1,000 today. Yet, the quest to produce larger amounts of short- and long-read data in a shorter span of time and at an even lower cost continues.

Since its inception, MGI Tech Co., Ltd. (MGI) has demonstrated its commitment to “turbocharge your sequencing”, and its latest ultra-high-throughput genetic sequencer DNBSEQ-T7* marks another technological breakthrough in both performance and cost. Powered by MGI’s DNBSEQ™ technology*, DNBSEQ-T7* makes sequencing more efficient and productive with advances in biochemical, fluidics, and optical systems.


High speed, high flexibility, and ultra-high throughput – the trifecta of sequencing innovation

DNBSEQ-T7* was developed independently by MGI using DNA nanoball and combinatorial probe anchor synthesis technologies to generate short reads at a very large scale – up to 60 human genomes per day. It maintains a powerful processing capability no matter whether it is a single-chip operation or has four chips running independently.


With a 20% increase in chip density, a single chip can achieve Tb-level data output and generate up to 6Tb of data per day, helping customers achieve powerful data output around-the-clock. Its ultra-fast speed means that PE150 sequencing now takes less than 24 hours to complete.


T7* delivers quadruple flowcell staging that allows simultaneous but independent operation of one to four flowcells, with different read lengths and applications to be processed independently in a single run, saving time and cost.


In addition, the core proprietary technology used in T7* ensures high accuracy, low duplicates, and low index hopping, while the launch of the new V2.0 sequencing reagent set* provides even higher and more stable data output. The new set* features upgrades that can further reduce the sequencing mismatch rate, duplicate rate, and sequencing cost of a single sample. Moreover, it can further improve the data utilization efficiency, as well as the precision and sensitivity of variation detection.


From pandemic response to precision medicine – diverse applications in scientific research and beyond

Designed for clinical and large-scale applications, DNBSEQ-T7* fully supports genome-wide sequencing, ultra-high-depth whole exome sequencing, epigenome sequencing, tumor large gene detection, and other application scenarios with its high speed, high flexibility and ultra-high throughput advantages.


Throughout the COVID-19 pandemic, T7* took centerstage in various genomic surveillance and sequencing efforts worldwide. Using the sequencer*, researchers at the Chinese Center for Disease Control and Prevention and their collaborators sequenced the 2019 novel coronavirus (2019-nCoV) pathogen from patient samples and unveiled its genomic characterization and epidemiology. In factthe viral RNA sequence generated using T7* was crucial in characterizing the virus and developing the diagnostics in the early days, as well as later vaccine development.


At the same time, T7* has empowered global businesses, such as Gencell Pharma in Colombia and GrandOmics in China, in the innovative development of precision medicine and healthcare services. It has also played a key role in scientific research in areas including gene editing.


As today’s most common gene-editing system, CRISPR-Cas9 has great potential for diverse uses, yet its off-target effects are a main limiting factor affecting its widespread application. In response, researchers in South Korea developed an effective and specific genome-editing tool, CRISPR-Cas12f1, and used T7* to verify its off-target effects based on Digenome-seq sequencing. The data, as enabled by T7*, confirmed that the system has high specificity and significantly decreased off-target sites. Meanwhile, the results showed that the sequencer can perform consistently and is able to produce high-quality, whole-genome sequencing data for testing the results and specificity of gene editing.


Comprehensive, one-stop service – tailored to any large-scale gene sequencing use

With high data quality and flexible operation mode, DNBSEQ-T7* provides comprehensive service for a diverse range of large-scale gene sequencing applications. Specifically, it is built with a one-stop product package: from sample pretreatment, library preparation and online sequencing to data analysis. It backs automatic cleaning and automatic recovery of sequencing slides, seamlessly linking to the next round of sequencing, and supporting running for a whole day. A high degree of automation maximizes T7’s* powerful data output capacity and effectively saves manpower and material costs.


In line with the ultra-high throughput of T7*, MGI also provides complete pre-sequencing and post-sequencing analysis packages to support the continuous output of ultra-high throughput data. In this package, whether it is nucleic acid extraction, library preparation, or accelerated analysis of off-line data, the optional automation equipment is adapted to fully enable the sequencer’s powerful data throughput.


In the genomics industry, the genetic sequencer serves as the starting point and provides the most basic support for the entire mid-stream and downstream sequencing services. Through continuous improvement in research and development capabilities, MGI is actively promoting the development of the upstream market by providing greater and more affordable choices for customers. In fact, the commercialization of DNBSEQ-T7* is expected to further reduce the cost of personal whole-genome sequencing to less than $500.


With this, MGI maintains as a leader in the gene-sequencing industry as it continues to break through the technical barriers of previous technologies, achieves better cost performance, and becomes an important driving force behind the development of the global genetic industry in the human genome era.


Find out more about DNBSEQ-T7* here.


*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal and Austria.


Quick Contact